Akumina Named A Strong Performer in 2020 Intranet Platforms Evaluation by Leading Independent Research Firm
16.6.2020 18:47:00 EEST | Business Wire | Press release
Akumina, the leading global Employee Experience Platform (EXP) software provider and one of INC Magazine’s Top 200 fastest growing companies in North America, announced today that they’ve been named a Strong Performer by Forrester Research, Inc. in The Forrester Wave™: Intranet Platforms, Q2 2020 report.
Akumina received the highest scores possible in seven criteria, including Personalization, Integration & Interoperability, and Design Tools.
Akumina’s inclusion in this evaluation is important especially to large enterprises working to improve employee experience, as it shows the strength and innovation of the organization’s technology. Many large enterprise customers like Banner Health, ING, and GlaxoSmithKline have already successfully partnered with Akumina.
“The Forrester Wave report is a well-respected resource for global organizations looking to partner with a software vendor ranked favorably in product quality, overall strategy, industry expertise and proven customer success,” says Akumina President and Co-Founder, David Maffei. “We feel being named a Strong Performer in the Forrester Wave reinforces our belief in the power of our platform and our strategy. It’s humbling and exciting to earn such a high honor from a respected independent third party like Forrester.”
Customer perspective is also considered an important part of the evaluation, which states, “Reference customers attest to the power of Akumina’s design tools, ease of content creation/editing, and ability to personalize communication.”
Akumina is laser focused on transforming the employee experience for medium and large enterprises around the globe with north of 4.5 million daily active users and customers using the platform in 80 countries and in over 60 different languages.
“Our intranet has become a unified, personalized platform connecting our employees to tools, information and each other. It empowers employees to take action, find solutions and share knowledge and experiences,” says Keith Kratochvil, Enterprise Architect at long-time Akumina customer the Principal Financial Group.
Akumina has also received recognition from organizations like ClearBox Consulting, The Tech Tribune, and CIO Review and has partnered with industry leaders such as Avanade, the leading digital innovator in the Microsoft ecosystem.
“Avanade is extremely excited with Akumina’s inclusion and placement in the 2020 Forrester Wave Report for Intranet Platforms. We took a strategic position in Akumina to help our clients to drive adoption and effective use of Digital Workplace tools at enterprise scale and we’ve seen our enterprise clients achieve strong results pivoting to a Digital-Hub-on-Akumina approach to reduce day-to-day friction in their organizations,” said Florin Rotar, Executive, Global Modern Workplace Lead at Avanade & Accenture Microsoft Business Group.
To learn more about Akumina, or to download a copy of the Forrester Wave™ Report on Intranet Platforms, please visit www.akumina.com.
About Akumina
Akumina is the employee experience platform that empowers global enterprises to quickly create personalized digital experiences that help every employee in every role work smarter, not harder. By offering a customizable, brandable and multilingual platform that seamlessly integrates with leading enterprise cloud applications, Akumina delivers a contextual, collaborative, and engaging workplace experience to every user on any device. Akumina’s customers include ING, Principal Financial Group, Whole Foods Market, GlaxoSmithKline, Vodafone, the Boston Red Sox and the Department of Defense. To learn more visit www.akumina.com or follow us on LinkedIn, Facebook and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005822/en/
Contact information
Michael Scott
VP of Marketing
Michael.Scott@akumina.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
